News & Media

July 18, 2024

NEWS RELEASE WEX PHARMACEUTICALS INC. ANNOUNCES ABSTRACT AND POSTER PRESENTATION ON HALNEURON® AT THE IASP 2024 WORLD CONGRESS ON PAIN

December 11, 2023

NEWS RELEASE: WEX PHARMACEUTICALS INC. COMMENCES ITS QUANTITATIVE SENSORY TESTING CLINICAL TRIAL EVALUATING THE IMPACT OF HALNEURON® ON HEALTHY VOLUNTEERS’ SENSORY PERCEPTIONS

September 25, 2023

WEX PHARMACEUTICALS INC. ANNOUNCES ABSTRACT AND POSTER PRESENTATION AT PAIN IN EUROPE XIII: THE 13TH CONGRESS OF THE EUROPEAN PAIN FEDERATION EFIC® ON THE LEAD COMPOUND, TTX (HALNEURON®)

September 12, 2023

WEX PHARMACEUTICALS INC. ANNOUNCES ABSTRACT AND POSTER PRESENTATION ON HALNEURON® AT PAIN IN EUROPE XIII: THE 13TH CONGRESS OF THE EUROPEAN PAIN FEDERATION EFIC®

August 22, 2023

News Brief: WEX Pharmaceuticals Inc. Announces Addition Of Intellectual Property For Its Novel Development And Use Of Tetrodotoxin (TTX) To Relieve Pain

March 21, 2023

News Brief: WEX Pharmaceuticals Inc. Enrolls In Korea As Part Of The Multinational Phase 2B Clinical Trial Evaluating The Efficacy And Safety Of Halneuron® In The Treatment Of Chemotherapy-Induced Neuropathic Pain

February 8, 2023

News Brief: WEX Pharmaceuticals Inc. Announces Management Changes

January 3, 2023

News Brief: WEX Pharmaceuticals Inc. Enrolls The First Patient In The Phase 2B Clinical Trial Evaluating The Efficacy And Safety Of Halneuron® In The Treatment Of Chemotherapy-Induced Neuropathic Pain

1 2